Section: Contact Information

First Name : **Lucie**
Last Name : **Turcotte**
Institution : **University of Minnesota**
Address 1 : **420 Delaware St SE**
Address 2 : **MMC 484**
City : **Minneapolis**
State/Province/Region : **MN**
Country : **US**
Zip/Postal Code : **55455**
Phone Number : **612-625-0032**
Alternate Phone Number : **612-626-2778**
Email Address : **turc0023@umn.edu**

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : **Yes**
The specific aims are clear and focused. : **Yes**
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**
Project Title : **Late and Very Late Acute Subsequent Leukemias among Survivors of Childhood Cancer**
Planned research population (eligibility criteria) :
CCSS cohort (1970-1999), focusing on individuals developing leukemia (N~65)
Proposed specific aims :
1. Identify treatment and patient characteristics associated with late (>5y-15 from diagnosis) and very late (>/=15y from diagnosis) subsequent leukemia risk
2. Evaluate cytogenetic alterations associated with late and very late subsequent leukemia and determine if cytogenetic alterations are associated with specific therapeutic exposures
3. Measure survival following late and very late subsequent leukemia

Will the project require non-CCSS funding to complete? : **Yes**
If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :
May require a small amount of CCSS CRA time to obtain cytogenetic reports. Funds would come form Turcotte K08 award or start-up funds.

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : **No**
Biological samples : **No**
Medical record data : **Yes**
If yes to any of the above, please briefly describe. :
Cytogenetics data from subsequent leukemia diagnosis

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy : **Primary**
Chronic Disease :
Psychology / Neuropsychology :
Genetics :
Cancer Control :
Epidemiology / Biostatistics : **Secondary**

Section: Outcomes or Correlative Factors

Late mortality : **Secondary**
Second Malignancy : **Primary**

Group: Health Behaviors

Tobacco :
Alcohol :
Physical activity :
Medical screening :
Other :
If other, please specify :

Group: Psychosocial

Insurance :
Marriage :
Education :
Employment :
Other :
If other, please specify :

Group: Medical Conditions

Hearing/Vision/Speech :
Hormonal systems :
Heart and vascular :
Respiratory :
Digestive :
Surgical procedures :
Brain and nervous system :
Other :
If other, please specify :

Group: Medications

Describe medications :

Group: Psychologic/Quality of Life

BSI-18 :
SF-36 :
CCSS-NCQ :
PTS :

PTG :
Other :
If other, please specify :

Group: Other

Pregnancy and offspring :
Family history :
Chronic conditions (CTCAE v3) :
Health status :

Group: Demographic

Age : **Correlative Factors**
Race : **Correlative Factors**
Sex : **Correlative Factors**
Other :
If other, please specify :

Group: Cancer treatment

Chemotherapy : **Correlative Factors**
Radiation therapy : **Correlative Factors**
Surgery :

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center : **Yes**
Local institutional statistician :
If local, please provide the name(s) and contact information of the statistician(s) to be involved. :
Will this project utilize CCSS biologic samples? : **No**
If yes, which of the following? :
If other, please explain :

Section: Other General Comments

Other General Comments :
I agree to share this information with St. Jude : **Yes**